Cellerant Therapeutics is getting another big boost from Uncle Sam. The Biomedical Advanced Research and Development Authority (BARDA) has provided the San Carlos, CA-based developer another $16.7 million, which comes on top of a previous $153.2 million award, to study treatments for radiation poisoning. In the unfortunate event of a nuclear attack or reactor meltdown, Cellerant's candidate CLT-008 (myeloid progenitor cells for infusion) could rescue survivors. Article